Beta-Sitosterol for Prostate: What the Clinical Trials Actually Used

By Alice Hess
Published September 12, 2026 · Reading time about 10 minutes

Affiliate disclosure: some links on this site are affiliate links. If you buy through them we may earn a commission at no extra cost to you. That never changes what the research says, and we publish negative findings about products we link to. This article is informational and is not medical advice.

What beta-sitosterol actually is

Beta-sitosterol is a plant sterol, a fat soluble compound built on the same four-ring backbone as cholesterol. It occurs naturally in small amounts in the oily fraction of many plants, including rice bran oil, wheat germ oil, corn oil, soybeans, peanuts, pumpkin seeds, and the wood and bark of pine and spruce trees. It is also present in saw palmetto berries, as part of the mixed fatty acid and sterol content that makes up a lipidosterolic extract.

That overlap is why the two supplements get confused. Saw palmetto's clinical research tested a concentrated extract of the whole berry, standardized to 320 mg per day of fatty acids and sterols combined.⁵ Beta-sitosterol's research tested something narrower: a purified preparation of one specific sterol, isolated on its own, usually sourced from pine, spruce, or soy rather than palmetto berries. For a full breakdown of what the saw palmetto trials used, see our saw palmetto dosage guide.

What the trials actually used and found

Beta-sitosterol's evidence base is small, old, and unusually consistent, the opposite pattern from saw palmetto's largest trials. Here is each trial in order.

The Berges 1995 trial (The Lancet)

Published in The Lancet, this German multicenter trial randomized 200 men with symptomatic BPH, recruited between April and October 1993, to either 20 mg of beta-sitosterol three times daily (60 mg per day total) or placebo for six months. The primary endpoint, a modified Boyarsky symptom score, fell by a mean of 6.7 points in the beta-sitosterol group versus 2.1 points with placebo (p < 0.01). The International Prostate Symptom Score fell 7.4 points versus 2.1 points. Peak urinary flow rose from 9.9 to 15.2 mL/s in the treatment group, and mean residual urine volume dropped from 65.8 to 30.4 mL, with no meaningful change in either measure in the placebo group. Prostate volume did not change significantly in either group.¹

The Klippel 1997 trial (British Journal of Urology)

This trial tested a branded beta-sitosterol product (Azuprostat) derived from species of pine, spruce, or Hypoxis, with beta-sitosterol as the main active component, not from saw palmetto. Across 13 study centers, 177 men with BPH took 130 mg of free beta-sitosterol daily for six months. Compared with placebo, the adjusted mean difference favored beta-sitosterol by 5.4 points on the IPSS (p < 0.01) and 0.9 points on a quality of life index. Peak urinary flow rose 4.5 mL/s more than placebo, and post void residual volume fell 33.5 mL more than placebo.²

The Wilt 1999 systematic review, and its Cochrane version

Tim Wilt and colleagues pooled the available randomized, placebo-controlled, double-blind trials of beta-sitosterol for BPH, searching MEDLINE, EMBASE, the Cochrane Library, and manufacturer records. Four trials met their criteria, covering 519 men, lasting between 4 and 26 weeks. Three used non-glucosidic beta-sitosterol preparations (like Berges and Klippel above) and one used a different form, 100 percent beta-sitosteryl-beta-D-glucoside. Pooled across the trials, beta-sitosterol improved IPSS by a weighted mean difference of 4.9 points (95% CI -6.3 to -3.5), improved peak urine flow by 3.91 mL/s (95% CI 0.91 to 6.90), and reduced residual urine volume by 28.62 mL (95% CI -41.42 to -15.83). Prostate size did not shrink. Withdrawal rates were similar between groups: 7.8 percent for beta-sitosterol versus 8.0 percent for placebo. The review's own conclusion is careful: "the evidence suggests non-glucosidic B-sitosterols improve urinary symptoms and flow measures," but "their long term effectiveness, safety and ability to prevent BPH complications are not known."³ A companion Cochrane Database of Systematic Reviews publication, covering the same 519 men and four trials, reached the identical numbers and the identical caveat about unknown long-term safety.⁴

What supplement labels actually sell, versus what the trials used

The research dose is narrow: 60 mg to 130 mg per day of a purified, free beta-sitosterol preparation. Very few consumer products state their dose that way. Common label patterns include a "Plant Sterol Complex" or "Beta-Sitosterol Blend" listed only as a total weight, a "Saw Palmetto Extract standardized to 45% sterols" claim that describes the extract's sterol percentage rather than a milligram amount of beta-sitosterol itself, or a multi-ingredient prostate formula where beta-sitosterol appears far down an ingredient list with no number attached at all.

None of that is necessarily dishonest, but none of it lets you compare a bottle to the trials above. A capsule advertising "500 mg Phytosterol Complex" could contain 130 mg of free beta-sitosterol, or considerably less, depending on what else is blended in. The same gap shows up with saw palmetto, where berry powder and true lipidosterolic extract are marketed under nearly identical wording despite very different sterol content; our guide to reading a saw palmetto label covers that comparison. The rule for beta-sitosterol is the same: look for the word "beta-sitosterol" specifically, a stated milligram amount per serving, and ideally third-party testing, and treat anything short of that as an unknown dose.

Beta-sitosterol versus saw palmetto: what the head-to-head evidence shows

Nobody has run a large trial pitting beta-sitosterol directly against saw palmetto extract, so there is no head-to-head data to cite. What exists is two separate, unequal bodies of evidence, and the contrast is worth sitting with.

Saw palmetto's biggest, most modern trials are its least favorable. The STEP trial, published in the New England Journal of Medicine in 2006, gave 225 men 160 mg of saw palmetto extract twice daily for a year and found no significant difference from placebo in symptom score (mean difference 0.04 point).⁵ The CAMUS trial, published in JAMA in 2011, escalated the dose in 369 men from 320 mg up to 960 mg per day over 72 weeks and still found no advantage over placebo.⁶ A 2024 update of the Cochrane review, pooling 27 studies and 4,656 men, concluded that Serenoa repens alone "provides little to no benefits" for LUTS due to benign prostatic enlargement, rating the evidence as high certainty.⁷ The National Center for Complementary and Integrative Health summarizes saw palmetto as "probably not helpful."⁸

Beta-sitosterol's trials run the opposite direction: smaller, older, and every one of the four trials in its systematic review pointed toward benefit. But beta-sitosterol's positive trials are also exactly the kind, small, decades old, and never independently repeated at scale, that tend to shrink once a field-defining modern trial finally gets funded. Saw palmetto went through that exact cycle: its early positive trials looked encouraging until STEP and CAMUS arrived. Beta-sitosterol has never been put through that test.

Safety: mild GI effects, sitosterolemia, and the ezetimibe interaction

Across the pooled trial data, beta-sitosterol looks safe short term. The Wilt systematic review found withdrawal rates of 7.8 percent with beta-sitosterol versus 8.0 percent with placebo, not a significant difference, and neither the Berges nor Klippel trial reported serious adverse events.³ Supplement safety literature outside these trials generally lists mild digestive complaints, such as nausea, gas, or loose stools, as the most common issue with plant sterols.

Two safety points are worth taking seriously anyway. The first is sitosterolemia, a rare inherited condition in which mutations in the ABCG5 or ABCG8 genes prevent the body from clearing plant sterols normally. According to MedlinePlus Genetics, people with sitosterolemia can develop tendon or tuberous xanthomas beginning in childhood, premature atherosclerosis that can lead to angina or heart attack, and hemolytic anemia from stiffened red blood cells. Only 80 to 100 cases have been described in the medical literature, though researchers estimate the true prevalence could be as high as 1 in 50,000 people, meaning some people carry it undiagnosed.⁹ Taking a concentrated beta-sitosterol supplement is not advisable for anyone who knows or suspects they have this condition.

The second is a drug interaction. Ezetimibe, a cholesterol-lowering medication, works specifically by blocking intestinal absorption of plant sterols, which is also the mechanism doctors use to treat sitosterolemia itself. A 2010 clinical report in the Journal of Atherosclerosis and Thrombosis documented ezetimibe reducing serum sitosterol levels by roughly half in sitosterolemia patients through this same absorption-blocking effect.¹⁰ Anyone taking ezetimibe, or any other cholesterol medication, should mention a beta-sitosterol supplement to their prescriber before combining the two.

Where the AUA guideline lands

Phytotherapy agents, including beta-sitosterol and saw palmetto, have a long history of sitting outside the American Urological Association's formal recommended treatment options for BPH. A guideline commentary published in Reviews in Urology notes that despite patient interest, phytotherapies were not included in the AUA's table of recommended treatments, and that European guideline panels separately called for longer, better standardized trials before plant extracts could be recommended for lower urinary tract symptoms.¹¹ The current AUA guideline on managing LUTS attributed to BPH continues that pattern.¹²

That is not a safety warning, it is a standard evidence bar: trials that are large, long, and built on a standardized, reproducible product. Beta-sitosterol's evidence, while consistent, has never cleared that bar the way alpha blockers or 5-alpha reductase inhibitors have.

An honest conclusion

Beta-sitosterol has the odd distinction of being both under-tested and quietly consistent. Every trial in its own systematic review found improvement in symptom score and flow measures, at doses of 60 mg to 130 mg per day of purified sterol, a result saw palmetto's larger, more recent trials could not replicate. But "consistent" is doing real work there: four trials and 519 men, all from one era, is not the same evidence base as 27 studies and 4,656 men. Nobody has repeated the beta-sitosterol trials with a modern, adequately powered design, so it is fair to call the data promising and fair to call it stale at the same time.

None of this makes beta-sitosterol a treatment for diagnosed BPH, and it is not a substitute for an actual evaluation. Urinary symptoms in men over 45 can come from an enlarged prostate, but also from infection, bladder dysfunction, diabetes, medication side effects, or prostate cancer, and no supplement sorts out which one you have. If you are comparing ingredient labels on a prostate supplement, including one like Prostadine, whose label does not list beta-sitosterol as an ingredient, none of the dosing evidence above transfers to a product that does not contain the compound in the first place. Our full ingredient breakdown covers what that formula does and does not disclose, and our prostate health hub rounds up the rest of what we have fact-checked on this topic.

Frequently asked questions